Circulating biomarkers are associated with disease severity of chronic hand eczema and atopic dermatitis

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Dokumenter

  • Fulltext

    Forlagets udgivne version, 2,68 MB, PDF-dokument

Background
Although chronic hand eczema (CHE) is a highly prevalent and disabling skin disease, it is currently unknown if CHE is associated with systemic inflammation.

Objectives
To characterize the plasma inflammatory signature of CHE.

Methods
Using Proximity Extension Assay technology, we assessed 266 inflammatory and cardiovascular disease risk proteins in the plasma of 40 healthy controls, 57 patients with atopic dermatitis (AD) with active lesions, 11 with CHE and a history of AD (CHEPREVIOUS_AD), and 40 with CHE and no history of AD (CHENO_AD). Filaggrin gene mutation status was also assessed. Protein expression was compared between groups and according to disease severity. Correlation analyses for biomarkers, and clinical- and self-reported variables, were performed.

Results
Very severe CHENO_AD was associated with systemic inflammation when compared with controls. Levels of T helper (Th)2- and Th1-, general inflammation and eosinophil activation markers increased with severity of CHENO_AD, primarily being significantly increased in very severe disease. Significant, positive correlations were found between markers from these pathways and severity of CHENO_AD. Moderate-to-severe but not mild AD displayed systemic inflammation. The Th2 markers C-C motif chemokine (CCL)17 and CCL13 (also known as monocyte chemotactic protein 4) were the top differentially expressed proteins in both very severe CHENO_AD and moderate-to-severe AD, showing a higher fold change and significance in AD. CCL17 and CCL13 levels further correlated positively with disease severity in both CHENO_AD and AD.

Conclusions
Systemic Th2-driven inflammation is shared between very severe CHE with no history of AD, and moderate-to-severe AD, suggesting that Th2 cell targeting could be effective in several CHE subtypes.
OriginalsprogEngelsk
TidsskriftBritish Journal of Dermatology
Vol/bind189
Udgave nummer1
Sider (fra-til)114-124
Antal sider11
ISSN0007-0963
DOI
StatusUdgivet - 2023

Bibliografisk note

Funding Information:
This study was funded by the LEO Foundation (GRANT ID: 114). The study was conducted independently of the LEO Foundation, which had no influence on study design, data analysis, preparation of the manuscript or decision to publish.

Funding Information:
We acknowledge nurse Anne Marie Topp for her valuable assistance with the recruitment of participants. We also acknowledge the Human Immune Monitoring Center and the computational resources provided by Scientific Computing at the Icahn School of Medicine at Mount Sinai. This study was funded by the LEO Foundation (GRANT ID: 114). The study was conducted independently of the LEO Foundation, which had no influence on study design, data analysis, preparation of the manuscript or decision to publish.

Funding Information:
Conflicts of interest C.B. is a consultant for Thorne HealthTech. J.P.T. is an advisor for AbbVie, Almirall, Arena Pharmaceuticals, Coloplast, OM Pharma, ASLAN Pharmaceuticals, UNION Therapeutics, Eli Lilly & Co., LEO Pharma, Pfizer, Regeneron and Sanofi-Genzyme, a speaker for AbbVie, Almirall, Eli Lilly & Co., LEO Pharma, Pfizer, Regeneron and Sanofi-Genzyme, and received research grants from Pfizer, Regeneron and Sanofi-Genzyme. The remaining authors declare they have no conflicts of interest.

Publisher Copyright:
© The Author(s) 2023. Published by Oxford University Press on behalf of British Association of Dermatologists.

ID: 396009110